Explain the limitations of monoaminergic antidepressants in treating MDD (e.g. delayed onset of effect, lack of response, TRD) Assess the MOA and most recent clinical and real-world evidence for innovative glutamatergic and neuromodulation therapies to address TRD Employ patient-focused approaches to develop personalized treatment plans, incorporating shared decision-making for individuals with TRD
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership · $99–598/yr
| New Membership – Standard | $349/yr |
| New Membership – Standard (2-year) | $598/yr |
| New Membership – Military/VA | $259/yr |
| New Membership – Student/Resident | $149/yr |
| Renewal Membership – Standard | $249/yr |
| Renewal Membership – Standard (2-year) | $478/yr |
+27 more tiers
Collected from the provider’s public pages · source
Specialties served/covered
- Child & Adolescent Psychiatry
- Clinical Informatics
- Communication & Shared Decision-Making
- General & Adult Psychiatry
- General Surgery
- Interventional Radiology
- Mood & Anxiety Disorders
- Neurology
- Neuroradiology
- Nuclear Medicine
- Pain Medicine
- Pediatric Neurology
- Practice Management & Ethics
- Psychopharmacology
- Psychotic Disorders
- Sleep Medicine
- Cross-Specialty
- Medical Subspecialties
- Neurology
- Pain & Palliative
- Psychiatry
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1 credit
- MOC · Up to 1 point
- Commercial Support
-
ReleasedNov 17, 2025
-
Last day to claim creditNov 18, 2026 5 weeks left
-
HMP Education Time to Change the Target: Optimal Use of Glutamatergic Antidepressants in Treatment-Resistant Depression
-
Neuroscience Education Institute +1 Fast and Curious: Exciting Advances in the Rapid-Acting and Targeted Treatment of Major Depressive Disorder
-
HMP Education Aiming Higher in MDD: Practical Strategies and Novel Monotherapies to Improve Outcomes
-
Med Learning Group Optimizing Outcomes in nAMD: Evidence-Based Selection, Sequencing, and Durability Strategies with Next-Generation Anti-VEGF Therapies
-
Vindico Medical Education, LLC Dry Eye Disease: What You Need to Know About Neurostimulatory Strategies
-
PRIME Education, Inc. (PRIME®) Sustained Strategies in Retina: Advancing Long-Acting Therapies for Retinal Vascular Disease
